BioMarin Pharmaceuticals BMRN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $520.42M-20.8% | $657.24M+25.5% | $523.88M+22.7% | ||
| $73.9M-7.1% | $79.56M-3.8% | $82.73M-0.6% | $83.25M-8.7% | $91.15M-5.5% | ||
| $187.17M+3.2% | $181.41M-2.7% | $186.42M+3.2% | $180.64M-0.2% | $181.02M-10.2% | ||
| —— | —— | —— | $116.33M+38.1% | $84.24M+50.2% | ||
| $8.05M+207% | $2.62M-0.3% | $2.63M-2.6% | $2.7M-10.9% | $3.03M-9.8% | ||
| —— | —— | —— | —— | $22.86M+14.9% | ||
| —— | —— | —— | —— | —— | ||
| $48.1M-58.9% | $116.93M-12.1% | $133.07M— | —— | —— | ||
| —— | —— | $19.22M-23.5% | $25.13M— | —— | ||
| $35.47M-8.1% | $38.57M-48.3% | $74.54M+15.9% | $64.33M+1.8% | $63.19M-14.3% | ||
| —— | —— | $26.42M+94.5% | $13.59M+0.5% | $13.52M-8.4% | ||
| $8.73M+88.8% | $4.63M+124% | -$19.47M-2.1% | -$19.08M-1.8% | -$18.74M+6.9% | ||
| -$3.67M+58.8% | -$8.89M— | —— | —— | —— | ||
| $874.25M+5.6% | $827.99M-9.4% | $913.98M+19.2% | $766.77M+9.5% | $700.26M+22.2% | ||
| $107.19M+4.0% | $103.04M+25.9% | $81.85M+13.9% | $71.86M-5.6% | $76.09M-10.9% | ||
| $292.39M-17.8% | $355.88M-4.1% | $371.14M-11.0% | $417.22M+10.4% | $377.86M-7.9% | ||
| $1.03B+204% | $337.8M-24.8% | $449.13M-12.1% | $511.11M-11.8% | $579.29M-8.5% | ||
| —— | —— | —— | —— | -$855.75K+25.0% | ||
| $339.52M+182% | -$414.24M-40.2% | -$295.39M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $45.37M-18.9% | $55.97M-3.8% | $58.17M-6.0% | $61.91M-6.7% | $66.39M-14.4% | ||
| —— | —— | —— | —— | —— | ||
| $806.4M+1,870% | -$45.55M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.02B+449% | $368.84M-35.8% | $574.66M+138% | $241.67M-19.9% | $301.81M+60.8% | ||
| $100.46M+4.4% | $96.21M+5.3% | $91.39M-5.6% | $96.77M+48.1% | $65.36M+14.1% | ||
| $3.89M-18.9% | $4.8M-11.4% | $5.42M-15.1% | $6.38M-11.4% | $7.21M-13.7% | ||
| $8.05M+207% | $2.62M-0.3% | $2.63M-2.6% | $2.7M-10.9% | $3.03M-9.8% | ||
| —— | —— | —— | —— | $22.86M+14.9% | ||
| -$21.2M-375% | -$4.46M— | —— | —— | —— | ||
| -$3.67M+58.8% | -$8.89M— | —— | —— | —— | ||
| $8.73M+88.8% | $4.63M+124% | -$19.47M-2.1% | -$19.08M-1.8% | -$18.74M+6.9% | ||
| —— | —— | —— | —— | -$855.75K+25.0% | ||
| $1.03B+204% | $337.8M-24.8% | $449.13M-12.1% | $511.11M-11.8% | $579.29M-8.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $4.75M-25.0% | ||
| $767.06M+5.8% | $724.96M-12.9% | $832.13M+19.7% | $694.91M+11.3% | $624.18M+28.1% | ||
| $767.06M+5.8% | $724.96M-12.9% | $832.13M+19.7% | $694.91M+11.3% | $624.18M+28.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioMarin Pharmaceuticals generate?
- BioMarin Pharmaceuticals (BMRN) generated $874.3M in operating cash flow over the trailing twelve months.
- What is BioMarin Pharmaceuticals's free cash flow?
- After $107.2M of capital expenditures, BioMarin Pharmaceuticals's free cash flow was $767.1M over the trailing twelve months, up 22.9% year over year.
- Where does BioMarin Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
